TY  - JOUR
AB  - BACKGROUND: High tumor budding and elevated systemic inflammation are adverse prognostic indicators in colorectal cancer. Its underlying mechanisms remain poorly understood. It is unclear whether systemic inflammation, angiogenesis, and cell-to-cell adhesion influence tumor budding. METHODS: We investigated n = 132 stage I-III colorectal cancer patients recruited at Huntsman Cancer Institute enrolled in the ColoCare Study. Tumor budding was evaluated using an evidence-based scoring system, and patient sera were analyzed for nine circulating biomarkers using the Meso Scale Discovery platform. We examined associations between biomarkers and tumor budding using multivariable linear regression models adjusted for age, sex, neoadjuvant treatment, stage, and non-steroidal anti-inflammatory drug use. RESULTS: The study population was predominantly non-Hispanic White (95%), with a mean age of 61 years; 56% were male. Most tumors were stage III (47%), located in the colon (64%), and exhibited low-grade tumor budding (58%). Soluble intercellular adhesion molecule 1 was inversely associated with tumor budding overall (M1: β = -0.57, p = 0.03), among females (M1: β = -0.81, p-value = 0.03) and later-onset (≥ 50 years) colorectal cancer (M1: β = -0.71, p-value = 0.008). C-reactive protein was positively associated with tumor budding in males (M1: β = 0.23, p = 0.001), while interleukin-8 (M1: β = 0.96, p-value = 0.01) and soluble vascular adhesion molecule 1 (M2: β = 1.48, p-value = 0.04) were positively associated with tumor budding in early-onset patients. However, these associations did not remain statistically significant after correction for multiple testing. CONCLUSION: Overall, our findings do not provide evidence of a significant association between biomarkers of systemic inflammation, angiogenesis, and cell-to-cell adhesion with tumor budding count. We observed patterns for some biomarkers, yet none remained statistically significant after correction for multiple testing. These findings provide preliminary insights for future studies. TRIAL REGISTRATION: ClinicalTrials.gov: NCT02328677.
AU  - Hausmann, O.*
AU  - Schobert, P.P.*
AU  - Ose, J.*
AU  - Himbert, C.*
AU  - Pletneva, M.*
AU  - Jedrzkiewicz, J.*
AU  - Nguyen, A.*
AU  - Lin, T.*
AU  - Warby, C.A.*
AU  - Hardikar, S.*
AU  - Peoples, A.R.*
AU  - Strehli, I.*
AU  - Huang, L.C.*
AU  - Cohan, J.N.*
AU  - Pickron, B.*
AU  - Scaife, C.*
AU  - Li, C.I.*
AU  - Grady, W.M.*
AU  - Shibata, D.*
AU  - Toriola, A.T.*
AU  - Schneider, M.*
AU  - Figueiredo, J.C.*
AU  - Siegel, E.M.*
AU  - Gigic, B.*
AU  - Herzig, S.
AU  - Ilozumba, M.N.*
AU  - Ulrich, C.M.*
C1  - 75613
C2  - 58245
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
TI  - Associations of biomarkers of systemic inflammation, angiogenesis, and cell-to-cell adhesion with tumor budding among early-onset and later-onset colorectal cancer patients.
JO  - Cancer Med.
VL  - 14
IS  - 18
PB  - Wiley
PY  - 2025
SN  - 2045-7634
ER  - 

TY  - JOUR
AB  - BACKGROUND: Breast cancer (BC) patients with a germline CHEK2 c.1100delC variant have an increased risk of contralateral BC (CBC) and worse BC-specific survival (BCSS) compared to non-carriers. AIM: To assessed the associations of CHEK2 c.1100delC, radiotherapy, and systemic treatment with CBC risk and BCSS. METHODS: Analyses were based on 82,701 women diagnosed with a first primary invasive BC including 963 CHEK2 c.1100delC carriers; median follow-up was 9.1 years. Differential associations with treatment by CHEK2 c.1100delC status were tested by including interaction terms in a multivariable Cox regression model. A multi-state model was used for further insight into the relation between CHEK2 c.1100delC status, treatment, CBC risk and death. RESULTS: There was no evidence for differential associations of therapy with CBC risk by CHEK2 c.1100delC status. The strongest association with reduced CBC risk was observed for the combination of chemotherapy and endocrine therapy [HR (95% CI): 0.66 (0.55-0.78)]. No association was observed with radiotherapy. Results from the multi-state model showed shorter BCSS for CHEK2 c.1100delC carriers versus non-carriers also after accounting for CBC occurrence [HR (95% CI): 1.30 (1.09-1.56)]. CONCLUSION: Systemic therapy was associated with reduced CBC risk irrespective of CHEK2 c.1100delC status. Moreover, CHEK2 c.1100delC carriers had shorter BCSS, which appears not to be fully explained by their CBC risk.
AU  - Morra, A.*
AU  - Schreurs, M.A.C.*
AU  - Andrulis, I.L.*
AU  - Anton-Culver, H.*
AU  - Augustinsson, A.*
AU  - Beckmann, M.W.*
AU  - Behrens, S.*
AU  - Bojesen, S.E.*
AU  - Bolla, M.K.*
AU  - Brauch, H.*
AU  - Broeks, A.*
AU  - Buys, S.S.*
AU  - Camp, N.J.*
AU  - Castelao, J.E.*
AU  - Cessna, M.H.*
AU  - Chang-Claude, J.*
AU  - Chung, W.K.*
AU  - Colonna, S.V.*
AU  - Couch, F.J.*
AU  - Cox, A.*
AU  - Cross, S.S.*
AU  - Czene, K.*
AU  - Daly, M.B.*
AU  - Dennis, J.*
AU  - Devilee, P.*
AU  - Dörk, T.*
AU  - Dunning, A.M.*
AU  - Dwek, M.*
AU  - Easton, D.F.*
AU  - Eccles, D.M.*
AU  - Eriksson, M.*
AU  - Evans, D.G.*
AU  - Fasching, P.A.*
AU  - Fehm, T.N.*
AU  - Figueroa, J.D.*
AU  - Flyger, H.*
AU  - Gabrielson, M.*
AU  - Gago-Dominguez, M.*
AU  - Garcia-Closas, M.*
AU  - García-Sáenz, J.A.*
AU  - Genkinger, J.*
AU  - Grassmann, F.*
AU  - Gündert, M.
AU  - Hahnen, E.*
AU  - Haiman, C.A.*
AU  - Hamann, U.*
AU  - Harrington, P.A.*
AU  - Hartikainen, J.M.*
AU  - Hoppe, R.*
AU  - Hopper, J.L.*
AU  - Houlston, R.S.*
AU  - Howell, A.*
AU  - Jakubowska, A.*
AU  - Janni, W.*
AU  - Jernström, H.*
AU  - John, E.M.*
AU  - Johnson, N.*
AU  - Jones, M.E.*
AU  - Kristensen, V.N.*
AU  - Kurian, A.W.*
AU  - Lambrechts, D.*
AU  - Le Marchand, L.*
AU  - Lindblom, A.*
AU  - Lubinski, J.*
AU  - Lux, M.P.*
AU  - Mannermaa, A.*
AU  - Mavroudis, D.*
AU  - Mulligan, A.M.*
AU  - Muranen, T.A.*
AU  - Nevanlinna, H.*
AU  - Nevelsteen, I.*
AU  - Neven, P.*
AU  - Newman, W.G.*
AU  - Obi, N.*
AU  - Offit, K.*
AU  - Olshan, A.F.*
AU  - Park-Simon, T.W.*
AU  - Patel, A.V.*
AU  - Peterlongo, P.*
AU  - Phillips, K.A.*
AU  - Plaseska-Karanfilska, D.*
AU  - Polley, E.C.*
AU  - Presneau, N.*
AU  - Pylkäs, K.*
AU  - Rack, B.*
AU  - Radice, P.*
AU  - Rashid, M.U.*
AU  - Rhenius, V.*
AU  - Robson, M.*
AU  - Romero, A.*
AU  - Saloustros, E.*
AU  - Sawyer, E.J.*
AU  - Schmutzler, R.K.*
AU  - Schuetze, S.*
AU  - Scott, C.*
AU  - Shah, M.*
AU  - Smichkoska, S.*
AU  - Southey, M.C.*
AU  - Tapper, W.J.*
AU  - Teras, L.R.*
AU  - Tollenaar, R.A.E.M.*
AU  - Tomczyk, K.*
AU  - Tomlinson, I.*
AU  - Troester, M.A.*
AU  - Vachon, C.M.*
AU  - van Veen, E.M.*
AU  - Wang, Q.*
AU  - Wendt, C.*
AU  - Wildiers, H.*
AU  - Winqvist, R.*
AU  - Ziogas, A.*
AU  - Hall, P.*
AU  - Pharoah, P.D.P.*
AU  - Adank, M.A.*
AU  - Hollestelle, A.*
AU  - Schmidt, M.K.*
AU  - Hooning, M.J.*
C1  - 68605
C2  - 54631
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
SP  - 16142-16162
TI  - Association of the CHEK2 c.1100delC variant, radiotherapy, and systemic treatment with contralateral breast cancer risk and breast cancer-specific survival.
JO  - Cancer Med.
VL  - 12
IS  - 15
PB  - Wiley
PY  - 2023
SN  - 2045-7634
ER  - 

TY  - JOUR
AB  - A comprehensive characterization of lung adenocarcinoma (LADC) clinical features is currently missing. We prospectively evaluated Caucasian patients with early-stage LADC. Patients with LADC diagnosed between 2011 and 2015 were prospectively assessed for lung resection with curative intent. Fifty clinical, pathologic, radiologic, and molecular variables were recorded. Patients were followed till death/study conclusion. The main findings were compared to a separate cohort from France. Of 1943 patients evaluated, 366 were enrolled (18.8%; 181 female; 75 never-smokers; 28% of registered Bavarian cases over the study period). Smoking and obstruction were significantly more prevalent in GLAD compared with adult Bavarians (P<0.0001). Ever-smoker tumors were preferentially localized to the upper lobes. We observed 120 relapses and 74 deaths over 704 cumulative follow-up years. Median overall and disease-free survival were >7.5 and 3.6years, respectively. Patients aged <45 or >65years, resected >60days postdiagnosis, with abnormal FVC/DLCOVA, N2/N3 stage, or solid histology had significantly decreased survival estimates. These were fit into a weighted locoregional LADC death risk score that outperformed pTNM7 in predicting survival in the GLAD and in our second cohort. We define the clinical gestalt of locoregional LADC and provide a new clinical tool to predict survival, findings that may aid future management and research design.
AU  - Klotz, L.V.
AU  - Courty, Y.*
AU  - Lindner, M.
AU  - Petit-Courty, A.*
AU  - Stowasser, A.*
AU  - Koch, I.*
AU  - Eichhorn, M.E.*
AU  - Lilis, I.*
AU  - Morresi-Hauf, A.*
AU  - Arendt, K.A.M.
AU  - Pepe, M.
AU  - Giopanou, I.*
AU  - Ntaliarda, G.*
AU  - Behrend, S.J.
AU  - Oplopoiou, M.*
AU  - Gissot, V.*
AU  - Guyetant, S.*
AU  - Marchand-Adam, S.*
AU  - Behr, J.
AU  - Kaiser, J.C.
AU  - Hatz, R.A.
AU  - Lamort, A.-S.
AU  - Stathopoulos, G.T.
C1  - 55579
C2  - 46421
CY  - 111 River St, Hoboken 07030-5774, Nj Usa
SP  - 1486-1499
TI  - Comprehensive clinical profiling of the Gauting locoregional lung adenocarcinoma donors.
JO  - Cancer Med.
VL  - 8
IS  - 4
PB  - Wiley
PY  - 2019
SN  - 2045-7634
ER  - 

TY  - JOUR
AB  - Cancer Medicine published by John Wiley & Sons Ltd. BACKGROUND: For Glioblastoma (GBM), various prognostic nomograms have been proposed. This study aims to evaluate machine learning models to predict patients' overall survival (OS) and progression-free survival (PFS) on the basis of clinical, pathological, semantic MRI-based, and FET-PET/CT-derived information. Finally, the value of adding treatment features was evaluated. METHODS: One hundred and eighty-nine patients were retrospectively analyzed. We assessed clinical, pathological, and treatment information. The VASARI set of semantic imaging features was determined on MRIs. Metabolic information was retained from preoperative FET-PET/CT images. We generated multiple random survival forest prediction models on a patient training set and performed internal validation. Single feature class models were created including "clinical," "pathological," "MRI-based," and "FET-PET/CT-based" models, as well as combinations. Treatment features were combined with all other features. RESULTS: Of all single feature class models, the MRI-based model had the highest prediction performance on the validation set for OS (C-index: 0.61 [95% confidence interval: 0.51-0.72]) and PFS (C-index: 0.61 [0.50-0.72]). The combination of all features did increase performance above all single feature class models up to C-indices of 0.70 (0.59-0.84) and 0.68 (0.57-0.78) for OS and PFS, respectively. Adding treatment information further increased prognostic performance up to C-indices of 0.73 (0.62-0.84) and 0.71 (0.60-0.81) on the validation set for OS and PFS, respectively, allowing significant stratification of patient groups for OS. CONCLUSIONS: MRI-based features were the most relevant feature class for prognostic assessment. Combining clinical, pathological, and imaging information increased predictive power for OS and PFS. A further increase was achieved by adding treatment features.
AU  - Peeken, J.C.
AU  - Goldberg, T.*
AU  - Pyka, T.*
AU  - Bernhofer, M.*
AU  - Wiestler, B.*
AU  - Kessel, K.A.
AU  - Tafti, P.D.*
AU  - Nüsslin, F.*
AU  - Braun, A.E.*
AU  - Zimmer, C.*
AU  - Rost, B.*
AU  - Combs, S.E.
C1  - 55408
C2  - 46113
SP  - 128-136
TI  - Combining multimodal imaging and treatment features improves machine learning-based prognostic assessment in patients with glioblastoma multiforme.
JO  - Cancer Med.
VL  - 8
IS  - 1
PY  - 2019
SN  - 2045-7634
ER  - 

TY  - JOUR
AB  - Cancer Medicine published by John Wiley & Sons Ltd. In patients undergoing surgical resection of brain metastases, the risk of local recurrence remains high. Adjuvant whole brain radiation therapy (WBRT) can reduce the risk of local relapse but fails to improve overall survival. At two tertiary care centers in Germany, a retrospective study was performed to evaluate the role of hypofractionated stereotactic radiotherapy (HFSRT) in patients with brain metastases after surgical resection. In particular, need for salvage treatment, for example, WBRT, surgery, or stereotactic radiosurgery (SRS), was evaluated. Both intracranial local (LF) and locoregional (LRF) failures were analyzed. A total of 181 patients were treated with HFSRT of the surgical cavity. In addition to the assessment of local control and distant intracranial control, we analyzed treatment modalities for tumor recurrence including surgical strategies and reirradiation. Imaging follow-up for the evaluation of LF and LRF was available in 159 of 181 (88%) patients. A total of 100 of 159 (63%) patients showed intracranial progression after HFSRT. A total of 81 of 100 (81%) patients received salvage therapy. Fourteen of 81 patients underwent repeat surgery, and 78 of 81 patients received radiotherapy as a salvage treatment (53% WBRT). Patients with single or few metastases distant from the initial site or with WBRT in the past were retreated by HFSRT (14%) or SRS, 33%. Some patients developed up to four metachronous recurrences, which could be salvaged successfully. Eight (4%) patients experienced radionecrosis. No other severe side effects (CTCAE≥3) were observed. Postoperative HFSRT to the resection cavity resulted in a crude rate for local control of 80.5%. Salvage therapy for intracranial progression was commonly needed, typically at distant sites. Salvage therapy was performed with WBRT, SRS, and surgery or repeated HFSRT of the resection cavity depending on the tumor spread and underlying histology. Prospective studies are warranted to clarify whether or not the sequence of these therapies is important in terms of quality of life, risk of radiation necrosis, and likelihood of neurological cause of death.
AU  - Bilger, A.*
AU  - Bretzinger, E.*
AU  - Fennell, J.*
AU  - Nieder, C.*
AU  - Lorenz, H.*
AU  - Oehlke, O.*
AU  - Grosu, A.*
AU  - Specht, H.M.*
AU  - Combs, S.E.
C1  - 53753
C2  - 44996
CY  - 1752 N St Nw, Washington, Dc 20036-2904 Usa
SP  - 2350-2359
TI  - Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection.
JO  - Cancer Med.
VL  - 7
IS  - 6
PB  - Amer Soc Microbiology
PY  - 2018
SN  - 2045-7634
ER  - 

TY  - JOUR
AB  - The heterogeneity of high-grade glioma recurrences remains an ongoing challenge for the interdisciplinary neurooncology team. Response to re-irradiation (re-RT) is heterogeneous, and survival data depend on prognostic factors such as tumor volume, primary histology, age, the possibility of reresection, or time between primary diagnosis and initial RT and re-RT. In the present pooled analysis, we gathered data from radiooncology centers of the DKTK Consortium and used it to validate the established prognostic score by Combs et al. and its modification by Kessel et al. Data consisted of a large independent, multicenter cohort of 565 high-grade glioma patients treated with re-RT from 1997 to 2016 and a median dose of 36 Gy. Primary RT was between 1986 and 2015 with a median dose of 60 Gy. Median age was 54 years; median follow-up was 7.1 months. Median OS after re-RT was 7.5, 9.5, and 13.8 months for WHO IV, III, and I/II gliomas, respectively. All six prognostic factors were tested for their significance on OS. Aside from the time from primary RT to re-RT (P = 0.074) and the reresection status (P = 0.101), all factors (primary histology, age, KPS, and tumor volume) were significant. Both the original and new score showed a highly significant influence on survival with P < 0.001. Both prognostic scores successfully predict survival after re-RT and can easily be applied in the routine clinical workflow. Now, further prognostic features need to be found to even improve treatment decisions regarding neurooncological interventions for recurrent glioma patients.
AU  - Combs, S.E.
AU  - Niyazi, M.*
AU  - Adeberg, S.*
AU  - Bougatf, N.*
AU  - Kaul, D.*
AU  - Fleischmann, D.F.*
AU  - Gruen, A.*
AU  - Fokas, E.*
AU  - Rödel, C.M.*
AU  - Eckert, F.*
AU  - Paulsen, F.*
AU  - Oehlke, O.*
AU  - Grosu, A.-L.*
AU  - Seidlitz, A.*
AU  - Lattermann, A.*
AU  - Krause, M.*
AU  - Baumann, M.*
AU  - Guberina, M.*
AU  - Stuschke, M.*
AU  - Budach, V.*
AU  - Belka, C.*
AU  - Debus, J.*
AU  - Kessel, K.A.
C1  - 53348
C2  - 44689
SP  - 1742-1749
TI  - Re-irradiation of recurrent gliomas: Pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK).
JO  - Cancer Med.
VL  - 7
IS  - 5
PY  - 2018
SN  - 2045-7634
ER  - 

TY  - JOUR
AB  - Cancer Medicine published by John Wiley & Sons Ltd. Brain metastases show a recurrence rate of about 50% after surgical resection. Adjuvant radiotherapy can prevent progression; however, whole-brain radiotherapy (WBRT) can be associated with significant side effects. Local hypofractionated stereotactic radiotherapy (HFSRT) is a good alternative to provide local control with minimal toxicity. In this multicenter analysis, we evaluated the treatment outcome of local HFSRT after resection brain metastases in 181 patients. Patient's characteristics, treatment data as well as follow-up data were collected and analyzed with special focus on local control, locoregional control and survival. After a median follow-up of 12.6 months (range 0.3–80.2 months), the crude rate for local control was 80.5%; 1- and 2-year local recurrence-free survival rates were 75% and 70% (median not reached). Resection cavity size was a significant predictor for local recurrence (P = 0.033). The median overall survival was 16.0 months. Both graded prognostic assessment score and recursive partitioning analysis were accurate predictors of survival. HFSRT leads to excellent local control and has a high potential to consolidate results after surgery; acute and late toxicity is low. Distant intracerebral metastases occur frequently during follow-up, and therefore, a close patient monitoring needs to be warranted if whole-brain radiotherapy is omitted.
AU  - Combs, S.E.
AU  - Bilger, A.*
AU  - Diehl, C.
AU  - Bretzinger, E.*
AU  - Lorenz, H.*
AU  - Oehlke, O.*
AU  - Specht, H.M.
AU  - Kirstein, A.
AU  - Grosu, A.*
C1  - 53752
C2  - 44995
CY  - 1752 N St Nw, Washington, Dc 20036-2904 Usa
SP  - 2319-2327
TI  - Multicenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastases.
JO  - Cancer Med.
VL  - 7
IS  - 6
PB  - Amer Soc Microbiology
PY  - 2018
SN  - 2045-7634
ER  - 

TY  - JOUR
AB  - Tumor cells educate immune effector cells in their vicinity by releasing factors that manipulate their phenotype and function. In fact, the thus generated immunosuppressive tumor microenvironment constitutes an integral part and a hallmark of solid tumors and contributes significantly to tumor development and immune escape. It has long been thought that soluble factors like prostaglandin E2 and TGF-β are the main mediators of these effects. But tumor cells also constantly release large number of extracellular vesicles (EVs), which are important conveyors of immune responses. We show here that tumor-derived EVs interact with primary monocytes and induce an activated phenotype, which is also observed in tumor-associated macrophages. Thus, both tumor-derived EVs and soluble factors together collaborate to form the immunosuppressive milieu of the tumor environment.
AU  - Gärtner, K.
AU  - Battke, C.
AU  - Dünzkofer, J.*
AU  - Hüls, C.
AU  - von Neubeck, B.
AU  - Kellner, M.
AU  - Fiestas, E.*
AU  - Fackler, S.
AU  - Lang, S.*
AU  - Zeidler, R.
C1  - 53340
C2  - 44579
SP  - 2013-2020
TI  - Tumor-derived extracellular vesicles activate primary monocytes.
JO  - Cancer Med.
VL  - 7
IS  - 5
PY  - 2018
SN  - 2045-7634
ER  - 

TY  - JOUR
AB  - A 3D microtissues using T47D and JIMT-1 cells were generated to analyze tissue-like response of breast cancer cells after combined human epidermal growth factor receptor 2 (HER2)-targeted treatment and radiation. Following lentiviral knockdown of HER2, we compared growth rate alterations using 2D monolayers, 3D microtissues, and mouse xenografts. Additionally, to model combined therapeutic strategies, we treated HER2-depleted T47D cells and 3D microtissues using trastuzumab (anti-HER2 antibody) in combination with irradiation. Comparison of HER2 knockdown with corresponding controls revealed growth impairment due to HER2 knockdown in T47D 2D monolayers, 3D microtissues, and xenografts (after 2, 12, and ≥40 days, respectively). In contrast, HER2 knockdown was less effective in inhibiting growth of trastuzumab-resistant JIMT-1 cells in vitro and in vivo. Combined administration of trastuzumab and radiation treatment was also analyzed using T47D 3D microtissues. Administration of both, radiation (5 Gy) and trastuzumab, significantly enhanced the growth inhibiting effect in 3D microtissues. To improve the predictive power of potential drugs-as single agents or in combination-here, we show that regarding tumor growth analyses, 3D microtissues are highly comparable to outcomes derived from xenografts. Considering increased limitations for animal experiments on the one hand and strong need of novel drugs on the other hand, it is indispensable to include highly reproducible 3D microtissue platform in preclinical analyses to validate more accurately the capacity of future drug-combined radiotherapy.
AU  - Falkenberg, N.
AU  - Höfig, I.
AU  - Rosemann, M.
AU  - Szumielewski, J.
AU  - Richter, S.
AU  - Schorpp, K.K.
AU  - Hadian, K.
AU  - Aubele, M.
AU  - Atkinson, M.J.
AU  - Anastasov, N.
C1  - 47694
C2  - 39410
CY  - Hoboken
SP  - 703-710
TI  - Three-dimensional microtissues essentially contribute to preclinical validations of therapeutic targets in breast cancer.
JO  - Cancer Med.
VL  - 5
IS  - 4
PB  - Wiley-blackwell
PY  - 2016
SN  - 2045-7634
ER  - 

TY  - JOUR
AB  - Past patterns of cancer disease and future changes in the demographic structure have a major influence on the projected incidences of human malignancies. In Germany, nearly a quarter of men and 20% of women die of cancer, and it is estimated that in Germany around 51% men and 43% women will develop cancer during lifetime. Here, we project the cancer incidence case number as well as the number of deaths for the most common cancers in the German population for the years 2020 and 2030. By 2030, prostate cancer will be the most common malignancy, surpassing breast cancer. Lung cancer will rank third most frequent cancer and will remain the most common cause of cancer-related mortality. Additionally, our projections show a marked increase in liver cancer cases with a continuous rise in liver cancer-related deaths. Finally, we project a constant increase in the incidence of pancreatic cancer. Based on our projections, pancreatic cancer will surpass colorectal and breast cancer to rank as the second most common cause of cancer-related deaths in Germany by 2030.
AU  - Quante, A.S.
AU  - Ming, C.
AU  - Rottmann, M.*
AU  - Engel, J.*
AU  - Boeck, S.*
AU  - Heinemann, V.*
AU  - Westphalen, C.B.*
AU  - Strauch, K.
C1  - 49027
C2  - 41557
CY  - Hoboken
SP  - 2649-2656
TI  - Projections of cancer incidence and cancer-related deaths in Germany by 2020 and 2030.
JO  - Cancer Med.
VL  - 5
IS  - 9
PB  - Wiley-blackwell
PY  - 2016
SN  - 2045-7634
ER  -